Regencell Bioscience Holdings Ltd (NASDAQ:RGC) — Market Cap & Net Worth
Market Cap & Net Worth: Regencell Bioscience Holdings Ltd (RGC)
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) has a market capitalization of $3.06 Billion ($3.06 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4774 globally and #1623 in its home market, demonstrating a 9.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regencell Bioscience Holdings Ltd's stock price $6.18 by its total outstanding shares 494488908 (494.49 Million). See Regencell Bioscience Holdings Ltd capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Regencell Bioscience Holdings Ltd Market Cap History: 2021 to 2026
Regencell Bioscience Holdings Ltd's market capitalization history from 2021 to 2026. Data shows change from $15.75 Billion to $3.06 Billion (-9.98% CAGR).
Index Memberships
Regencell Bioscience Holdings Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.12% | #120 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #549 of 3165 |
Weight: Regencell Bioscience Holdings Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Regencell Bioscience Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regencell Bioscience Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RGC by Market Capitalization
Companies near Regencell Bioscience Holdings Ltd in the global market cap rankings as of August 3, 2026.
Key companies related to Regencell Bioscience Holdings Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Regencell Bioscience Holdings Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Regencell Bioscience Holdings Ltd's market cap moved from $15.75 Billion to $ 3.06 Billion, with a yearly change of -9.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.06 Billion | -70.57% |
| 2025 | $10.38 Billion | +325.10% |
| 2024 | $2.44 Billion | -52.95% |
| 2023 | $5.19 Billion | -62.35% |
| 2022 | $13.79 Billion | -12.43% |
| 2021 | $15.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Regencell Bioscience Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.06 Billion USD |
| MoneyControl | $3.06 Billion USD |
| MarketWatch | $3.06 Billion USD |
| marketcap.company | $3.06 Billion USD |
| Reuters | $3.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more